Veristat’s Bold Thinking and World Class Clinical, Regulatory and Commercialization Capabilities Allow the Company to Successfully Tackle Complex Therapy Development Challenges to Meet the Goals of its Clients
Veristat congratulates Awakn for being awarded UK State Funding to Identify Optimal Pathway to Market In UK & US For Its Lead Clinical Development Program – Ketamine-Assisted Therapy For Alcohol Use Disorder
Acquires Swiss-based multi-disciplinary consultancy SFL (Solutions for Life Sciences) to accelerate the development of and access to innovative treatments